THE ROLE OF MICROVESICLES FROM BLOOD PRODUCTS IN OSTEOARTHROSIS
Krems an der Donau – OrthoSera GmbH joined to a special project and research with Donau University Krems the roles of microvesicles. The project is co-financed by the European Regional Development Fund.
The chronic degenerative disease, osteoarthritis affects approximately 60% of the world’s population and is characterized by progressive degradation of the cartilage. Patients suffer from major pain, disability and dramatic loss of quality of life. In addition to medical treatments, the transplantation of the body’s own cartilage cells or the replacement of the entire damaged knee by a prosthesis is the only way to improve the clinical picture of osteoarthrosis.
A new regenerative therapy approach is the use of products derived from the patient’s blood. HypACT serum and Platelet-rich plasma (PRP) are among the most promising. These products represent an accumulation of various factors (mainly growth factors) that should accelerate the healing of cartilage defects.
OrthoSera GmbH has developed the CE-certified hypACT inject device with which the patient’s blood can be taken, centrifuged and processed within the same medical treatment. The resulting hypACT serum is injected into the diseased site using hypACT inject.
Extracellular vesicles, which include microvesicles as well as exosomes and apoptotic bodies, are considered to be a novel approach to cell-cell communication as they transport bioactive molecules from one cell to another, where they trigger a specific biological response. The aim of this project is to isolate and characterize microvesicles from the two blood products PRP and hypACT serum, in order to subsequently determine their regenerative potential in the fight against osteoarthrosis.